Guardant Health said Tricare will cover its Shield blood‑based colorectal cancer screening test with no copay for eligible active‑duty service members and dependents aged 45 and older at average risk. Guardant noted Shield already had FDA approval as a primary screening option in mid‑2024 and earlier coverage by the VA and CMS ADLT designation. Shield analyzes genomic, epigenomic and proteomic signals from blood to detect colorectal cancer; Tricare coverage expands access within the US military health system and removes a financial barrier for beneficiaries. Guardant framed the decision as part of an ongoing effort to broaden payor coverage for liquid‑biopsy screening tools. The expansion strengthens Shield’s commercial positioning amid growing adoption of blood‑based cancer screening and continued payer evaluation of diagnostic utility and cost‑effectiveness.